Even though respiratory viruses are one of the most common triggers for asthma exacerbations, not all of these viruses affect patients equally. There is no strong evidence supporting that patients with asthma have a higher risk of becoming seriously ill from coronavirus disease 2019 (CO­VID-19), although recent reports from the USA and the UK suggest that asthma is much more common in children and adults with mild to severe COVID-19 than has previously been reported in Asia and in Europe. As in previous severe acute respiratory syndrome (SARS) outbreaks, patients with asthma, especially children, appear to be less susceptible to the coronavirus with a low rate of asthma exacerbations. A different expression of viral receptors and T2 inflammation can be responsible for different outcomes. Future studies focused on asthma and on other allergic disorders are needed to provide a greater understanding of the impact of underlying asthma and allergic inflammation on COVID-19 susceptibility and disease severity. However, for the moment, it is crucial that asthmatic patients maintain their controller medication, from inhaled corticosteroids to biologics, without making any dose adjustments on their own or stopping the medication. New data are emerging daily, rapidly updating our understanding of this novel coronavirus.
Int Arch Allergy Immunol

中文翻译：

---

哮喘与 2019 年冠状病毒病大流行：文献综述。

尽管呼吸道病毒是哮喘发作最常见的诱因之一，但并非所有这些病毒对患者的影响都相同。尽管美国和英国最近的报告表明哮喘在患有轻度哮喘的儿童和成人中更为常见，但没有强有力的证据表明哮喘患者因 2019 年冠状病毒病 (COVID-19) 而患重病的风险更高。与此前亚洲和欧洲报道的情况相比，新冠肺炎 (COVID-19) 的情况更为严重。与之前的严重急性呼吸综合征（SARS）爆发一样，哮喘患者，尤其是儿童，似乎不太容易感染冠状病毒，哮喘发作率也较低。病毒受体和 T2 炎症的不同表达可能导致不同的结果。未来需要针对哮喘和其他过敏性疾病开展研究，以更好地了解潜在哮喘和过敏性炎症对 COVID-19 易感性和疾病严重程度的影响。然而，目前至关重要的是，哮喘患者维持其控制药物（从吸入皮质类固醇到生物制剂），而无需自行调整剂量或停止用药。新数据每天都在出现，迅速更新了我们对这种新型冠状病毒的理解。
Int Arch 过敏免疫